Compass Therapeutics announced the appointment of veteran biopharma leaders Yu Liu, M.D., Ph.D., MBA, as chief medical officer and Lynne Sullivan as chief financial officer. Dr. Liu, who most recently served as vice president and head of early clinical development at Pfizer, will oversee Compass' development of a deep pipeline of immuno-oncology and autoimmune disease candidates. Ms. Sullivan, who most recently served as senior vice president, finance at Biogen, will lead financial planning and management at Compass at a time of significant growth for the company.

Prior to Pfizer, Dr. Liu led Biogen's early clinical development effort in rare disease, with an emphasis on cell and gene therapy.